Development and manufacturing of life-saving therapies based on human proteins, including treatments for bleeding disorders, autoimmune diseases, and critical care.
D
CSR Analysis score
The organization's commitment is in the lower half of comparable organizations that position themselves on at least one CSR axis.
EmpCo Directive — September 27, 2026
We analyzed the websites of over 250,000 companies, including Octapharma's, to extract CSR initiatives and communications containing risky environmental claims.
Greenwashing risk score + your position within your sector
+250,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: September 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Octapharma
B
Manufacturing of pharmaceuticals based on human proteins derived from human cell lines and plasma. Development of treatments for hematology, immunology, and intensive care.
Fresenius Kabi
B
Development and provision of life-saving drugs and medical technologies for patients with serious and chronic diseases, including pharmaceuticals, clinical nutrition, and medical devices.
Amgen France
A
Research, development, and manufacturing of innovative therapies for serious diseases using biotechnology.
Initiatives identified among leaders
Augmentation approvisionnement énergie renouvelable pour atteindre neutralité carbone d’ici 2027.
“Amgen France participe à la stratégie mondiale du ...” - Amgen FranceRéduction globale de l'impact environnemental par des actions structurées
“Le groupe s'engage à réduire son impact environnem...” - Fresenius KabiRéduction des inégalités d’accès aux soins et thérapies innovantes pour les populations vulnérables
“Actions visant à réduire les inégalités d’accès au...” - Amgen France74% of similar organizations communicate on CSR issues
+796 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports